Clinical Trial Results:
A randomized, double-blind, parallel-group, placebo- and active calibrator-controlled
study assessing the clinical benefit of SAR153191 subcutaneous (SC) on top of methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who have failed previous tumor necrosis factor-alpha (TNF-α) antagonists.
Summary
|
|
EudraCT number |
2010-021020-94 |
Trial protocol |
DE IT HU CZ ES |
Global completion date |
15 Sep 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
05 Oct 2016
|
First version publication date |
05 Oct 2016
|
Other versions |
|
Summary report(s) |
ACT11575 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.